If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Transcode Therapeutics (RNAZ)
Squarespace, Inc. (SQSP)
Procore Technologies, Inc. (PCOR)
Oatly Group Ab (OTLY)
Ziprecruiter, Inc. (ZIP)
Priced IPO
Save Foods (SVFD)
Vera Therapeutics, Inc. (VERA)
Digital Brands Group, Inc. (DBGI)
Ipower Inc. (IPW)
Global-e Online Ltd. (GLBE)
Similarweb Ltd. (SMWB)
Flora Growth (FLGC)
Anebulo Pharmaceuticals (ANEB)
Bowman Consulting Group Ltd. (BWMN)
Onion Global Limited (OG)
Waterdrop Inc. (WDH)
Talaris Therapeutics, Inc. (TALS)
Valneva Se (VALN)
Five Star Bancorp (FSBC)
The Honest Company Inc. (HNST)
Alfi, Inc. (ALF)
Red Cat Holdings (RCAT)
Werewolf Therapeutics Inc. (HOWL)
Vaccitech Plc. (VACC)
Endeavor Group Holdings (EDR)
More companies

Angion Biomedica Corp. (ANGN)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Their lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that they are currently evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart. Within AKI, they are currently evaluating ANG-3777's ability to improve kidney function and reduce the severity of transplant-associated AKI, also known as delayed graft function (DGF), in patients at risk for kidney dysfunction, as well as for the treatment of AKI associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI). They are also evaluating ANG-3777 for indications within acute lung injury (ALI), with their primary focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. They are advancing multiple programs for the treatment of fibrotic diseases, leading with ANG-3070, a tyrosine kinase inhibitor (TKI), and their inhibitor of rho kinase 2 (ROCK2). They also continue to develop other preclinical product candidates, including their CYP11B2 (aldosterone synthase) inhibitors, which they are investigating for the purpose of targeting aldosterone-related fibrotic diseases.
Jay R. Venkatesan Gregory S. Curhan
Employees Founded
53 1998


Address: 51 Charles Lindbergh Boulevard Uniondale, New York 11553

Telephone: (415) 655-4899

Web page:

IPO information

First Trade Date 2/5/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 5
Shares Revised (MM) 5
Expected offer amount (MM) $75
Realized offer amount(MM) $80

Financial Data (last reporting year)

Market Cap (MM) $431.7
Revenues (MM) $3.12
Net Income (Loss) (MM) $-67.25


What do you think will happen with the ANGN share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Cowen

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Cowen/ Stifel
HC Wainwright/ Oppenheimer

Sector: Healthcare

Tweets about $ANGN

Tweets volume:

RT volume:


Google Trends Stats